Select Biosciences Ltd

News Headlines

DiaKine Therapeutics and Kinexum Metabolics to Develop Combination Treatment to Type 1 Diabetes
07 May 2008
DiaKine’s Lisofylline and Kinexum’s INGAP peptide combo therapy is set for Phase 2 clinical trial.

CreoSalus Names New President
06 May 2008
CreoSalus have named Craig Kalmer as President/CEO of the Advanced ChemTech and ThuraMed divisions of CreoSalus.

AnaSpec’s Published References Passes 600
05 May 2008
As compiled by Stanford University’s Highwire Press, the number of published papers that cite AnaSpec’s products has passed 600.

Compugen Announces Discovery of Blood Based Biomarker for Diagnosis of Lung Cancer
30 April 2008
Compugen discovers the peptide, a potential blood based biomarker for lung cancer, using its immunoassay diagnostics discovery platform.

CMD Bioscience and Research Foundation of SUNY on Behalf of Stony Brook University Sign Exclusive Licensing Agreement
28 April 2008
The deal gives CMD Bioscience exclusive control of a computational method for predicting protein-protein and protein-peptide binding affinities.

AnaSpec FRET-based MMP Substrates Used in Double Differential In Vivo Zymography
22 April 2008
AnaSpec FRET-based MMP substrates were recently used in a double differential in vivo zymography study at the University of New Brunswick.

New England Peptide Names Antibody Project Manager
18 April 2008
NEP has named Kristin Byrne to work directly with customers to provide antigen/sequence design support and advisory services.

Vermillion Announces Issuance of U.S. Patent Covering the Discovery of Novel Forms of Brain Natriuretic Peptide
12 April 2008
Company believes that the discovery could lead to the development of a next-generation assay to improve diagnosis and treatment of cardiovascular disease.

  
Select Conferences